260 related articles for article (PubMed ID: 33785968)
1. Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19.
Liu JB; Arockiaraj M; Arulperumjothi M; Prabhu S
Int J Quantum Chem; 2021 May; 121(10):e26617. PubMed ID: 33785968
[TBL] [Abstract][Full Text] [Related]
2. QSPR/QSAR analysis of some eccentricity based topological descriptors of antiviral drugs used in COVID-19 treatment via $ \mathscr{D}\varepsilon $- polynomials.
Sarkarai D; Desikan K
Math Biosci Eng; 2023 Sep; 20(9):17272-17295. PubMed ID: 37920055
[TBL] [Abstract][Full Text] [Related]
3. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
4. Topological indices and QSPR/QSAR analysis of some antiviral drugs being investigated for the treatment of COVID-19 patients.
Kirmani SAK; Ali P; Azam F
Int J Quantum Chem; 2021 May; 121(9):e26594. PubMed ID: 33612855
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs.
Chopra D; Boparai JK; Bhandari B; Srivastava A; Gupta R
Infect Disord Drug Targets; 2021; 21(7):e160921189260. PubMed ID: 33342420
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of COVID-19 drugs in a real clinical setting.
Chiu MN; Bhardwaj M; Sah SP
Eur J Clin Pharmacol; 2022 May; 78(5):733-753. PubMed ID: 35088108
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
Habler K; Brügel M; Teupser D; Liebchen U; Scharf C; Schönermarck U; Vogeser M; Paal M
J Pharm Biomed Anal; 2021 Mar; 196():113935. PubMed ID: 33548872
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
Apaydın ÇB; Çınar G; Cihan-Üstündağ G
Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
[TBL] [Abstract][Full Text] [Related]
10. Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
Michaud V; Dow P; Al Rihani SB; Deodhar M; Arwood M; Cicali B; Turgeon J
Clin Transl Sci; 2021 Jan; 14(1):20-28. PubMed ID: 32888379
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
12. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
Kröker A; Tirzīte M
Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
[TBL] [Abstract][Full Text] [Related]
13. An Update on Current Therapeutic Drugs Treating COVID-19.
Wu R; Wang L; Kuo HD; Shannar A; Peter R; Chou PJ; Li S; Hudlikar R; Liu X; Liu Z; Poiani GJ; Amorosa L; Brunetti L; Kong AN
Curr Pharmacol Rep; 2020; 6(3):56-70. PubMed ID: 32395418
[TBL] [Abstract][Full Text] [Related]
14. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
Dragojevic Simic V; Miljkovic M; Stamenkovic D; Vekic B; Ratkovic N; Simic R; Rancic N
Int J Clin Pract; 2021 Mar; 75(3):e13825. PubMed ID: 33156564
[TBL] [Abstract][Full Text] [Related]
15. Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.
Sahin G; Akbal-Dagistan O; Culha M; Erturk A; Basarir NS; Sancar S; Yildiz-Pekoz A
J Pharm Sci; 2022 Oct; 111(10):2652-2661. PubMed ID: 35691607
[TBL] [Abstract][Full Text] [Related]
16. Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective.
Duru CE; Umar HIU; Duru IA; Enenebeaku UE; Ngozi-Olehi LC; Enyoh CE
Environ Anal Health Toxicol; 2021 Jun; 36(2):e2021010-0. PubMed ID: 34130375
[TBL] [Abstract][Full Text] [Related]
17. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
[TBL] [Abstract][Full Text] [Related]
18. An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
Indari O; Jakhmola S; Manivannan E; Jha HC
Front Pharmacol; 2021; 12():632677. PubMed ID: 33762954
[TBL] [Abstract][Full Text] [Related]
19. Molecular Descriptors of Some Chemicals that Prevent COVID-19.
Mondal S; De N; Pal A; Gao W
Curr Org Synth; 2021; 18(8):729-741. PubMed ID: 33292123
[TBL] [Abstract][Full Text] [Related]
20. Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters.
Kuroda K; Li C; Dhangar K; Kumar M
Sci Total Environ; 2021 Jul; 776():145740. PubMed ID: 33647647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
